FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington, | D.C. | 20549 |
|-------------|------|-------|
|-------------|------|-------|

| STATEMENT | OF CHANGES IN | N BENEFICIAL | OWNERSHIP |
|-----------|---------------|--------------|-----------|
| | | | |

| OMB APPROVAL | | | | | | | | | |
|--------------------------|-----------|--|--|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | | | |
| Estimated average burden | | | | | | | | | |
| hours per response: | 0.5 | | | | | | | | |

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* GRIFFIN MICHELLE RENEE | | | | | | 2. Issuer Name and Ticker or Trading Symbol Adaptive Biotechnologies Corp [ADPT] | | | | | | | | 5. Relationship (Check all appl X Direct | | cable) | g Pers | son(s) to Iss 10% Ov | | |
|----------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|--------------------|----------------------------------------------|-----------------|-----------------------------------------|------------------------------------------------------------------------------------|----------------------------------------|-----------------|-------------------------------------------------------|-----------------------|-------------------|-----------|------------------------------------------|------------------------------------------------|-----------------------|-----------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|---------------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------|
| (Last) C/O ADA | APTIVE BI | rst) OTECHNOLOG | (Middle) GIES CO | RP. | 06/ | 3. Date of Earliest Transaction (Month/Day/Year) 06/14/2021 | | | | | | | | | | below) | | | Other (: below) | |
| (Street) SEATTL (City) | E W | | 98102 (Zip) | | 4. If | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | | 6. Indi Line) X | | | | | |
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | | | | | | | | |
| 1. Title of Security (Instr. 3) 2. Transa Date (Month/D | | | | Execution Date, | | | , Transaction Disposed Code (Instr. 5) | | | rities Acquired (A) o | | | 5. Amou Securiti Benefici Owned | es ally Following | Form (D) o | n: Direct r Indirect istr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | | |
| | | | | | | | | | Cod | e V | Amou | Amount (A | | Pric | e | Transac (Instr. 3 | ction(s) | | | (111511.4) |
| Common Stock 06/14 | | | | | /2021 | 2021 | | M ⁽¹ | | 2,5 | 00 | A | \$7.8 | | 4,004 | | | D | | |
| Common Stock 06/14 | | | | | /2021 | | S ⁽¹ | | 2,5 | 2,500 | | \$3 | 8.56 | 6 1,504 | | | D | | | |
| | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | | 3A. Deem Executior if any (Month/Da | Date, | 4. Transaction Code (Instr. B) | | n of | | 6. Date Exercisa Expiration Date (Month/Day/Yea | | e | Amount of | | f g Securi | D Si (li | 8. Price of Derivative Security (Instr. 5) | 9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4) | y Ow For Oir or (I) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| | | | | | Code | v | (A) | (D) | Date Exercis | | Expiratio Date | | itle | Amou or Numb of Share | er | | | | | |
| Stock Option (Right to | \$7.8 | 06/14/2021 | | | M ⁽¹⁾ | | | 2,500 | (2) | | 04/23/202 | | Common Stock | 2,50 | 0 | \$0.00 | 73,500 | | D | |

Explanation of Responses:

- $1. \ The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020.$
- 2. The options vested with respect to 1/4 of such shares on March 28, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

Remarks:

/s/ Michelle Griffin by Eric Billings, attorney-in-fact

06/16/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.